Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946088 | 0.85 | AR (0.46) | ARIMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL4077294 | 0.80 | ALDH1A1 (0.50) | ARIMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL6767370 | 0.75 | KDM4E (0.41) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL19614570 | 0.74 | AR (0.54) | ARALDH1A1PGR | |
| SCHEMBL6762758 | 0.70 | MAPK8 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL15716231 | 0.69 | S1PR1 (0.42) | ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL5203586 | 0.68 | MAPT (0.40) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL24495415 | 0.68 | ALDH1A1 (0.49) | ARIMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL3272602 | 0.68 | ALDH1A1 (0.49) | ARIMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL4739057 | 0.68 | AR (0.40) | ARKDM4EUSP2ALDH1A1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | AR 32/4885IMPDH2 1684/4885IMPDH1 1000/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | AR 33/4885IMPDH2 1555/4885IMPDH1 909/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | AR 34/4885IMPDH2 1502/4885IMPDH1 900/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | AR 32/4885IMPDH2 1599/4885IMPDH1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.